Shedir Pharma Srl Unipersonale
MIL:SHE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.52
4.86
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shedir Pharma Srl Unipersonale
Shedir Pharma Srl Unipersonale
Operating Expenses
Shedir Pharma Srl Unipersonale
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
Operating Expenses
-€27.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
Operating Expenses
-€21.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
Operating Expenses
-€895.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
P
|
Pierrel SpA
MIL:PRL
|
Operating Expenses
-€19.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
8%
|
|
|
Friulchem SpA
MIL:FCM
|
Operating Expenses
-€4.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Shedir Pharma Srl Unipersonale
Glance View
Shedir Pharma Group SpA operates as a holding company which engages in the research and development of nutraceuticals and medical devices. The company is headquartered in Mercato San Severino, Salerno and currently employs 71 full-time employees. The company went IPO on 2019-07-23. The firm markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.
See Also
What is Shedir Pharma Srl Unipersonale's Operating Expenses?
Operating Expenses
-27.3m
EUR
Based on the financial report for Dec 31, 2023, Shedir Pharma Srl Unipersonale's Operating Expenses amounts to -27.3m EUR.
What is Shedir Pharma Srl Unipersonale's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-5%
Over the last year, the Operating Expenses growth was -24%. The average annual Operating Expenses growth rates for Shedir Pharma Srl Unipersonale have been -13% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
